Details:
Inofolic is a natural health product, combining myo-inositol and folic acid in a unique soft-gel capsule for women living with PCOS. Inofolic® helped 70% of women with PCOSii to regulate their menstrual cycles throughout the 16-week study period.
Lead Product(s): Inositol,Folic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Inofolic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
The acquisition accelerates Cosette’s women’s health portfolio, with a differentiated, commercial stage, patent protected product, Intrarosa (prasterone), the only prescription drug providing both estrogen and androgen for the treatment of moderate-to-severe dyspareunia.
Lead Product(s): Prasterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Intrarosa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 08, 2023
Details:
As part of the agreement, Duchesnay will explore opportunities to register ANNOVERA with local regulatory agencies in these regions and will invest in the Population Council’s research activities to develop new innovative contraceptive products.
Lead Product(s): Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Population Council
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 30, 2020
Details:
BIJUVA is a once-daily combination of estradiol and progesterone in a single oral capsule that will be available in two strengths in Canada indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus.
Lead Product(s): Estradiol,Progesterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Bijuva
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: TherapeuticsMD
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
In Canada, IMVEXXY is approved for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA).
Lead Product(s): Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Imvexxy
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
The aim of this partnership is to provide Duchesnay USA's Osphena® (ospemifene) to women suffering from vaginal symptoms related to menopause, with the possibility of having this conversation with a healthcare provider in the comfort and privacy of their own home.
Lead Product(s): Ospemifene
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Plushcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 19, 2020